The association of elevated 2',5'-oligoadenylate-dependent RNase L with lung cancer correlated with deficient enzymatic activity and decreased capacity of RNase L dimerization

Lung Cancer

Volumn 78, Issue 1, 2012, Pages 30-38

  Yin, Huijing ^a   Zhou, Aimin ^b   Dai, Yalei ^a  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b CLEVELAND STATE UNIVERSITY   (United States)

Author keywords

Dimerization; Lung cancer; RNase L; RNase L activity; RNase L inhibitor; RRNA cleavage

Indexed keywords

2',5' OLIGOADENYLATE RIBONUCLEASE; MESSENGER RNA; RIBONUCLEASE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER GROWTH; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; LUNG CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

ADENINE NUCLEOTIDES; CELL LINE, TUMOR; ENDORIBONUCLEASES; ENZYME ACTIVATION; HUMANS; LUNG NEOPLASMS; OLIGORIBONUCLEOTIDES; PROTEIN MULTIMERIZATION; PROTEIN SYNTHESIS INHIBITORS;

EID: 84866143733     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2012.07.010     Document Type: Article

References (35)

1. Youlden D.R., Cramb S.M., Baade P.D. The international epidemiology of lung cancer: geographical distribution and secular trends. J Thorac Oncol 2008, 3:819-831.
2. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics, 2009, CA. Cancer J Clin 2009, 59:225-249.
3. Egleston B.L., Meireles S.I., Flieder D.B., Clapper M.L. Population-based trends in lung cancer incidence in women. Semin Oncol 2009, 36:506-515.
4. Scagliotti G.V., Longo M., Novello S. Nonsmall cell lung cancer in never smokers. Curr Opin Oncol 2009, 21:99-104.
5. Li Z.G., Zhao J., Du Y.H., Park H.R., Sun S.Y., Bernal-Mizrachi L., et al. Down-regulation of 14-3-3ζ suppresses anchorage- independent growth of lung cancer cells through anoikis activation. PNAS 2008, 105:162-167.
6. Karna P., Sharp S.M., Yates C., Prakash S., Aneja R. EM011 activates a survivin-dependent apoptotic program in human non-small cell lung cancer cells. Mol Cancer 2009, 8:93.
7. Bhattacharya R., Kowalski J., Larson A.R., Brock M., Alani R.M. Id1 promotes tumor cell migration in nonsmall cell lung cancers. J Oncol 2010, 2010:856105.
8. Okudela K., Yazawa T., Ishii J., Woo T., Mitsui H., Bunai T., et al. Down-regulation of FXYD3 expression in human lung cancers: its mechanism and potential role in carcinogenesis. Am J Pathol 2009, 175:2646-2656.
9. Carpten J., Nupponen N., Isaacs S., Sood R., Robbins C., Xu J., et al. Germline mutations in the ribonuclease L gene in families showing linkage with HPC1. Nat Genet 2002, 30:181-184.
10. Rokman A., Ikonen T., Seppala E.H., Nupponen N., Autio V., Mononen N., et al. Germline alterations of the RNASEL gene, a candidate HPC1 gene at 1q25, in patients and families with prostate cancer. Am J Hum Genet 2002, 70:1299-1304.
11. Daugherty S.E., Hayes R.B., Yeager M., Andriole G.L., Chatterjee N., Huang W.Y., et al. RNASEL Arg462Gln polymorphism and prostate cancer in PLCO. Prostate 2007, 67:849-854.
12. Xiang Y., Wang Z., Murakami J., Plummer S., Klein E.A., Carpten J.D., et al. Effects of RNase L mutations associated with prostate cancer on apoptosis induced by 2',5'-oligoadenylates. Cancer Res 2003, 63:6795-6801.
13. Krüger S., Silber A.S., Engel C., Görgens H., Mangold E., Pagenstecher C., et al. Arg462Gln sequence variation in the prostate-cancer-usceptibility gene RNASEL and age of onset of hereditary non-polyposis colorectal cancer: a case-control study. Lancet Oncol 2005, 6:566-572.
14. Wang L., Zhou A., Vasavada S., Dong B., Nie H., Church J.M., et al. Elevated levels of 2',5'-linked oligoadenylate-dependent ribonuclease L occur as an early event in colorectal tumorigenesis. Clin Cancer Res 1995, 1:1421-1428.
15. Zhou A., Paranjape J.M., Hassei B.A., Nie H., Shan S., Galinski B., et al. Impact of Rnase L overexpression on viral and cellular growth and death. J Interf Cytok Res 1998, 18:953-961.
16. Hassel B.A., Zhou A., Sotomayor C., Maran A., Silverman R.H. A dominant negative mutant of 2-5A-dependent RNase suppresses antiproliferative and antiviral effects of interferon. EMBO J 1993, 12:3297-3304.
17. Zhou A., Paranjape J., Brown T.L., Nie H., Naik S., Dong B., et al. Interferon action and apoptosis are defective in mice devoid of 2',5'-oligoadenylate-dependent RNase L. EMBO J 1997, 16:6355-6363.
18. Li X.L., Blackford J.A., Hassel B.A. RNase L mediates the antiviral effect of interferon through a selective reduction in viral RNA during encephalomyocarditis virus infection. J Virol 1998, 72:2752-2759.
19. Li X.L., Blackford J.A., Judge C.S., Liu M., Xiao W., Hassel B.A. RNase-L-dependent destabilization of interferon-induced mRNAs. A role for the 2-5A system in attenuation of the interferon response. J Biol Chem 2000, 275:8880-8888.
20. Andersen J.B., Mazan-Mamczarz K., Zhan M., Gorospe M., Hassel B.A. Ribosomal protein mRNAs are primary targets of regulation in RNase-L-induced senescence. RNA Biol 2009, 6:305-315.
21. Leitner W.W., Hwang L.N., Deveer M.J., Zhou A., Silverman R.H., Williams B.R.G., et al. Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways. Nat Med 2003, 9:33-39.
22. Bisbal C., Martinand C., Silhol M., Lebleu B., Salehzada T. Cloning and characterization of a RNAse L inhibitor. A new component of the interferon-regulated 2-5A pathway. J Biol Chem 1995, 270:13308-13317.
23. Ren Y., Li Y., Tian D. Role of the ABCE1 gene in human lung adenocarcinoma. Oncol Rep 2012, 27:965-970.
24. Maor D., Klein M.E., Kenady D.E., Chretien P.B., Mardiney M.R. Carcinoma of the lung and cigarette smoking effect on serum ribonuclease activity. JAMA 1978, 239:2766-2768.
25. Rusch L., Dong B., Silverman R.H. Monitoring activation of ribonuclease L by 2',5'-oligoadenylates using purified recombinant enzyme and intact malignant glioma cells. Methods Enzymol 2001, 342:10-20.
26. Urisman A., Molinaro R.J., Fischer N., lummer S.J.P., Casey G., Klein E.A., et al. Identification of a novel gammaretrovirus in prostate tumors of patients homozygous for R462Q RNASEL variant. PLoS Pathog 2006, 2:e25.
27. Dong B., Silverman R.H. 2-5A-dependent RNase molecules dimerize during activation by 2-5A. J Biol Chem 1995, 270:4133-4137.
28. Silverman R.H., Zhou A., Auerbach M.B., Kish D., Gorbachev A., Fairchild R.L. Skin allograft rejection is suppressed in mice lacking the antiviral enzyme, 2',5'-oligoadenylate-dependent RNase L. Viral Immunol 2002, 15:77-83.
29. Li X.L., Ezelle H.J., Kang T.J., Zhang L., Shirey K.A., Harro J., et al. An essential role for the antiviral endoribonuclease RNase-L, in antibacterial immunity. PNAS 2008, 105:20816-20821.
30. Madsen B.E., Ramos E.M., Boulard M., Duda K., Overgaard J., Nordsmark M., et al. Germline mutation in RNASEL predicts increased risk of head and neck uterine cervix and breast cancer. PLoS One 2008, 3:e2492.
31. Martinand C., Salehzada T., Silhol M., Lebleu B., Bisbal C. RNase L inhibitor (RLI) antisense constructions block partially the down regulation of the 2-5A/RNase L pathway in encephalomyocarditis-virus (EMCV)-infected cells. Eur J Biochem 1998, 254:238-247.
32. Martinand C., Montavon C., Salehzada T., Silhol M., Lebleu B., Bisbal C. RNase L inhibitor is induced during human immunodeficiency virus type 1 infection and down regulates the 2-5A/RNase L pathway in human T cells. J Virol 1999, 73:290-296.
33. Casey G., Neville P.J., Plummer S.J., Xiang Y., Krumroy L.M., Klein E.A. RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases. Nat Genet 2002, 32:581-583.
34. Rennert H., Bercovich D., Hubert A., Abeliovich D., Rozovsky U., Bar-Shira A., et al. A novel founder mutation in the RNASEL gene, 471delAAAG, is associated with prostate cancer in Ashkenazi Jews. Am J Hum Genet 2002, 71:981-984.
35. Gileadi O., Lorberboum H., de Groot N., Hochberg A.A. Location of RNase and RNase inhibitor on free cytoplasmic mRNA-protein particles from human placenta. Mol Biol Rep 1984, 9:241-244.